Oro facial clefts pose a large psychological and economic burden for the families and society. The number of years lost in a person’s life caused by these disabilities can be assessed by calculating the Years lived with disability (YLD), a component of the Disability Adjusted Life Years (DALY) method. It is used for the evaluation of economic impact and to quantify the disease burden. Over a period of four years, this cross-sectional study was carried out at the orthodontics Department of BSMMU, Bangladesh. 55 adult male and female patients of 15-30 years were enrolled in the study. Everyone completed their treatment at the time of the interview. The number of DALYs averted after the treatment of these patients was calculated. Cost effectiveness of treatment was assessed by comparing the cost per DALY averted with the WHO-provided GDP threshold. If the patients were untreated, they would have a total of 1,314.35 years lived with disability, considering the disease onset at 0 years of life up to the expected standard life expectancy of 72 years. Because of the patients’ treatment, a total of 372.41 years of living with disability (YLD) have been averted. Our study found that the available treatments for clefts are cost-effective in our country. As the economic gain that calculated, focused on a small proportion of the DALY averted and cost-effectiveness, it advocates for broader implementation of such a method to address other health interventions.

The authors have declared no competing interest.

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Ethical clearance has been taken from the IRB of the Bangabandhu Sheikh Mujib Medical University (BSMMU), Date: 12-03-2018, No. - BSMMU/2018/3022.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

We confirm that the data supporting the findings of this study will be shared upon reasonable request.